Just in:
Superland Announced Annual Results for 2023, 2023 Net Profit Increased approximately 39.5% to approximately HK$22.2 million as Compared to the 2022 Adjusted One // Arvind Kejriwal Gets International Heft Against The Deshi Vishwaguru // Andertoons by Mark Anderson for Wed, 27 Mar 2024 // Experts come together to support updating the city’s nature conservation masterplan // In Lok Sabha Polls In Punjab, AAP Is Advantageously Placed As Against Its Three Rivals // Hullabaloo About Electoral Bonds May End Up As A Whimper Pre And Post Poll // Renewables Surge Sets Record, But Global Equity Lags // HSBC Streamlines Gold Investment for Hong Kong Residents with Tokenized Product // Universal Language for Healthcare: General Authority Embraces Global Coding System // Infineon and HD Korea Shipbuilding & Offshore Engineering jointly develop ship electrification technology // Employer Obligations Tighten: 30-Day Deadline for Emirati Employee Registration with GPSSA // Arvind Kejriwal Was Used By BJP In 2011 Movement To Take On The Congress // Near Miss at Kolkata Airport: IndiGo Plane Makes Contact with Stationary Air India Express // Hong Kong Seen Granting Mainland Investors Access to Crypto via ETFs // AI Boost for Galaxy Devices: Samsung Expands One UI 6.1 Update // Study: Stainless steel circular economy significantly reduces the risk of climate change in Thailand // Ajman Celebrates Conclusion of Ramadan Activities with Grand Ceremony // 2024 Lok Sabha Election Is A Historic Battle Against The Advent Of Fascism In India // Hope for Respite as UAE Endorses UN Plea for Gaza Truce // Sunshine’s Debut Features Leave Tech World Scratching Its Head //
HomeBiz TechIs Lou Gehrig’s Disease Finally Curable? FDA Approves New ALS Treatment : HEALTH : Tech Times

Is Lou Gehrig’s Disease Finally Curable? FDA Approves New ALS Treatment : HEALTH : Tech Times

ADVERTISEMENT

U.S. federal health regulators have approved a new drug for amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease. The drug called Radicava or edaravone, is the second drug to be greenlighted by the FDA for the condition after more than 20 years.

Radicava is manufactured by MT Pharma America, a subsidiary of Mitsubishi Tanabe Pharma Corporation in Japan. It is given by intravenous infusion and will cost more than $145,000 per year.

ALS

ALS is a progressive neurodegenerative disease that affects the nerve cells in the brain and the spinal cord that are responsible for making muscles work. The condition causes the nerve cells to lose their ability to initiate and control muscle movement leading to paralysis and death.

Most of those with the condition die from respiratory failure, usually between three to five years after the symptoms started to appear.

Cure Remains Elusive

While the approval of a new ALS treatment offers new option for those with the condition, it does not provide a cure for the disease, which affects about 12,000 to 15,000 Americans, according to figures from the Centers for Disease Control and Prevention.

In a six-month study conducted in Japan, the drug was found to slow down the progression of the disease. The first drug approved by the FDA for ALS, Riluzole can increase survival of patients by two or three months but it is not yet clear if Radicava has an effect on survival.

The new drug was approved not because it extended survival, but because it was found that the symptoms in patients who use it deteriorate more slowly, which means that for those given the new treatment, their condition will still get worse albeit this would happen more slowly.

In the study, 137 patients were randomly assigned to receive Radivaca or placebo. After six months, the conditions of those who were given the drug declined less than those who were given placebo.

At the end of the study period, those in the Radicava group scored about 2.5 points better on a 48-point scale that measure the disease’s severity. MT Pharma vice president of medical affairs Jean Hubble, said that the treatment appears most beneficial in patients who were still at the earliest stage of their disease.

Researchers are not certain how the medicine works, but it seems to sop up the free radicals that are partly responsible for the progress of the condition.

Hope For Better Treatment

The ALS Association, a national non-profit organization fighting Lou Gehrig’s Disease, applauded the approval and expressed its optimism for the availability of more therapies for those suffering from ALS in the near future.

The money raised from the ALS Ice Bucket Challenge that spread on social media in 2014 has helped fund important developments in the research about the disease, which could eventually lead to better treatments. Research funded by the proceeds of the ice bucket challenge, for instance, has identified a gene responsible for ALS.



“We hope today’s announcement signals the beginning of a new chapter in the fight against this terrible disease,” the ALS association said. “There are several drugs to treat ALS currently in clinical trials and we are hopeful that people living with ALS have even more therapies available to them sooner rather than later.”

© 2017 Tech Times, All rights reserved. Do not reproduce without permission.

(Via TechTimes)

ADVERTISEMENT

ADVERTISEMENT
Just in:
Emirates Post Speeds Up Deliveries for GCC with Special Day // Hong Kong Seen Granting Mainland Investors Access to Crypto via ETFs // 2024 Lok Sabha Election Is A Historic Battle Against The Advent Of Fascism In India // Andertoons by Mark Anderson for Thu, 28 Mar 2024 // Superland Announced Annual Results for 2023, 2023 Net Profit Increased approximately 39.5% to approximately HK$22.2 million as Compared to the 2022 Adjusted One // Experts come together to support updating the city’s nature conservation masterplan // Lisboeta Macau’s world first LINE FRIENDS PRESENTS CASA DE AMIGO and BROWN & FRIENDS CAFE & BISTRO has officially opened // In Lok Sabha Polls In Punjab, AAP Is Advantageously Placed As Against Its Three Rivals // Hullabaloo About Electoral Bonds May End Up As A Whimper Pre And Post Poll // The World’s First & Wettest Party: “S2O Hong Kong Songkran Music Festival” proudly returns Get an immersive water and music experience on 8-9 June during Dragon Boat Festival long weekend at Central Harbourfront Event Space! // Ajman Celebrates Conclusion of Ramadan Activities with Grand Ceremony // Infineon and HD Korea Shipbuilding & Offshore Engineering jointly develop ship electrification technology // Universal Language for Healthcare: General Authority Embraces Global Coding System // Andertoons by Mark Anderson for Wed, 27 Mar 2024 // Court Sides with Coinbase on Wallet Service, But Staking Program Remains in Limbo // Study: Stainless steel circular economy significantly reduces the risk of climate change in Thailand // Sharpening the Focus: Sharjah Health Department Refines Evaluation Criteria for “Healthy Schools Programme” // Party Nominees Refusing To Contest: Major Perception Threat For BJP // Employer Obligations Tighten: 30-Day Deadline for Emirati Employee Registration with GPSSA // AI Boost for Galaxy Devices: Samsung Expands One UI 6.1 Update //